AZ Doubles Down On Diabetes, Buys Out Bristol’s Share in Alliance
This article was originally published in The Pink Sheet Daily
AstraZeneca will acquire all of Bristol’s interests in their current diabetes alliance. In doing so, AZ believes its geographic reach and scale in assets and capabilities position it to succeed, while Bristol retreats from diabetes to focus on specialty biologics, notably its PD-1 franchise.
You may also be interested in...
US President Paul Hudson talked in an interview at the J.P. Morgan Healthcare conference about the company’s budding oncology portfolio, upcoming launches and growing optimism as the 2017 return-to-growth goal approaches.
With a focus on specialty drugs, Bristol wants to be known for more than immuno-oncology. To that end, specialty development head Douglas Manion is charged with leading innovation in immunology, virology and cardiovascular, genetically defined and fibrotic disease.
The company launched three diabetes drugs in 2014, just after breaking off a joint venture with Bristol-Myers and taking over full control of the business. U.S. President Paul Hudson talked about the evolution of AstraZeneca’s diabetes business – and where it stands today – in a recent interview.